Triple

T4850547
Position Surface form Disambiguated ID Type / Status
Subject MedImmune E108402 entity
Predicate alternativeName P39 FINISHED
Object MedImmune, LLC E108402 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: MedImmune, LLC | Statement: [MedImmune, alternativeName, MedImmune, LLC]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: MedImmune, LLC
Context triple: [MedImmune, alternativeName, MedImmune, LLC]
  • A. MedImmune chosen
    MedImmune is a biotechnology company best known as the biologics research and development arm of AstraZeneca, focusing on innovative therapies such as vaccines and monoclonal antibodies.
  • B. Genmab
    Genmab is a Danish biotechnology company specializing in the development of antibody-based cancer therapies.
  • C. Genentech
    Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
  • D. Regeneron Pharmaceuticals
    Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
  • E. Janssen Biotech
    Janssen Biotech is a biopharmaceutical company known for developing and manufacturing innovative biologic therapies, including the blockbuster monoclonal antibody Remicade.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69bd440a89548190a5f14ba6da6b97dc completed March 20, 2026, 12:56 p.m.
NER Named-entity recognition batch_69bd6d1ffad48190bec7be4a3b5ebb9c completed March 20, 2026, 3:52 p.m.
NED1 Entity disambiguation (via context triple) batch_69be5cdefda8819095fbc04446bf32f5 completed March 21, 2026, 8:54 a.m.
Created at: March 20, 2026, 1:25 p.m.